Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia.

IF 7 2区医学 Q1 ONCOLOGY

Chinese Journal of Cancer Research Pub Date : 2024-10-30 DOI:10.21147/j.issn.1000-9604.2024.05.06

Yuewen Wang, Xianli Gao, Ting Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Xia Yan, Xiaodong Mo, Xiaojun Huang

{"title":"Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia.","authors":"Yuewen Wang, Xianli Gao, Ting Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Xia Yan, Xiaodong Mo, Xiaojun Huang","doi":"10.21147/j.issn.1000-9604.2024.05.06","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to compare the quality-adjusted time without symptoms or toxicity (Q-TWiST) in acute myeloid leukemia (AML) patients who received haploidentical-related donor (HID) and identical sibling donor (ISD) hematopoietic stem cell transplantation (HSCT).Methods: Five clinical health states were defined: toxicity (TOX), acute graft-versus-host disease (GVHD), chronic GVHD (cGVHD), time without symptoms and toxicity (TWiST) and relapse (REL). The equation used in this study was as follows: Q-TWiST=UTOX × TOX + UTWiST × TWiST + UREL × REL + UaGVHD × aGVHD + UcGVHD × cGVHD.Results: A total of 239 AML patients were enrolled. We established a mathematical model, i.e., Q-TWiST HID HSCT > Q-TWiST ISD HSCT, to explore the range of utility coefficients satisfying the inequality. Based on the raw data, the utility coefficient is equivalent to the following inequality: [Formula: see text][Formula: see text]. The model showed that when [Formula: see text], [Formula: see text], and [Formula: see text] were within the range of 0-1, as well as when [Formula: see text] was within the range of 0-0.569, the inequality Q-TWiST HID HSCT > Q-TWiST ISD HSCT was valid. According to the results of the ChiCTR1800016972 study, the median coefficients of TOX, acute GVHD (aGVHD), and cGVHD were 0.56 (0.41-0.76), 0.56 (0.47-0.72), and 0.54 (0.37-0.79), respectively. We selected a series of specific examples of the coefficients, i.e., [Formula: see text]=0.5, [Formula: see text]=0.05, [Formula: see text]=0.5, and [Formula: see text]=0.5. The Q-TWiST values of ISD and HID HSCT were 896 and 900 d, respectively (P=0.470).Conclusions: We first observed that Q-TWiST was comparable between AML patients receiving HID HSCT and those receiving ISD HSCT.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"36 5","pages":"530-544"},"PeriodicalIF":7.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2024.05.06","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aimed to compare the quality-adjusted time without symptoms or toxicity (Q-TWiST) in acute myeloid leukemia (AML) patients who received haploidentical-related donor (HID) and identical sibling donor (ISD) hematopoietic stem cell transplantation (HSCT).

Methods: Five clinical health states were defined: toxicity (TOX), acute graft-versus-host disease (GVHD), chronic GVHD (cGVHD), time without symptoms and toxicity (TWiST) and relapse (REL). The equation used in this study was as follows: Q-TWiST=U_TOX × TOX + U_TWiST × TWiST + U_REL × REL + U_aGVHD × aGVHD + U_cGVHD × cGVHD.

Results: A total of 239 AML patients were enrolled. We established a mathematical model, i.e., Q-TWiST HID HSCT > Q-TWiST ISD HSCT, to explore the range of utility coefficients satisfying the inequality. Based on the raw data, the utility coefficient is equivalent to the following inequality: [Formula: see text][Formula: see text]. The model showed that when [Formula: see text], [Formula: see text], and [Formula: see text] were within the range of 0-1, as well as when [Formula: see text] was within the range of 0-0.569, the inequality Q-TWiST HID HSCT > Q-TWiST ISD HSCT was valid. According to the results of the ChiCTR1800016972 study, the median coefficients of TOX, acute GVHD (aGVHD), and cGVHD were 0.56 (0.41-0.76), 0.56 (0.47-0.72), and 0.54 (0.37-0.79), respectively. We selected a series of specific examples of the coefficients, i.e., [Formula: see text]=0.5, [Formula: see text]=0.05, [Formula: see text]=0.5, and [Formula: see text]=0.5. The Q-TWiST values of ISD and HID HSCT were 896 and 900 d, respectively (P=0.470).

Conclusions: We first observed that Q-TWiST was comparable between AML patients receiving HID HSCT and those receiving ISD HSCT.

查看原文本刊更多论文

急性髓性白血病患者接受单倍体相关捐献者与同胞捐献者造血干细胞移植的无症状、无毒性质量调整时间分析。

目的我们旨在比较接受单倍体相关供体（HID）和同胞姐妹供体（ISD）造血干细胞移植（HSCT）的急性髓性白血病（AML）患者无症状或毒性的质量调整时间（Q-TWiST）：定义了五种临床健康状态：毒性（TOX）、急性移植物抗宿主疾病（GVHD）、慢性GVHD（cGVHD）、无症状和毒性时间（TWiST）和复发（REL）。本研究采用的公式如下Q-TWiST=UTOX × TOX + UTWiST × TWiST + UREL × REL + UaGVHD × aGVHD + UcGVHD × cGVHD：共有 239 名急性髓细胞白血病患者入选。我们建立了一个数学模型，即 Q-TWiST HID HSCT > Q-TWiST ISD HSCT，以探索满足不等式的效用系数范围。根据原始数据，效用系数等价于以下不等式：[公式：见正文][公式：见正文]。模型显示，当[公式：见正文]、[公式：见正文]和[公式：见正文]在 0-1 范围内，以及当[公式：见正文]在 0-0.569 范围内时，不等式 Q-TWiST HID HSCT > Q-TWiST ISD HSCT 成立。根据 ChiCTR1800016972 研究的结果，TOX、急性 GVHD（aGVHD）和 cGVHD 的中位系数分别为 0.56（0.41-0.76）、0.56（0.47-0.72）和 0.54（0.37-0.79）。我们选择了一系列具体的系数实例，即[公式：见正文]=0.5、[公式：见正文]=0.05、[公式：见正文]=0.5 和[公式：见正文]=0.5。ISD和HID造血干细胞移植的Q-TWiST值分别为896和900 d（P=0.470）：我们首先观察到，接受HID造血干细胞移植的AML患者与接受ISD造血干细胞移植的患者的Q-TWiST相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Journal of Cancer Research 医学-肿瘤学

自引率

9.80%

发文量

1726

审稿时长

4.5 months

期刊介绍： Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.